Cartana was acquired by US-based 10X Genomics for $41.2 million.
Cartana, a Stockholm, Sweden-based tech developer of a platform used for research of brain cell analysis, announced that it was acquired by San Francisco, US-based 10x Genomics.
The deal was made for a total of $41.2 million, which includes a $7 million earnout. Cartana, which is currently located at Karolinska Institutet, will continue to be based in Stockholm.
Cartana, founded in 2017 and led by CEO Malte Kühnemund, is developing a technology that maps the brain based on cell analysis and image data with a resolution all the way down to the single cell level. The product, called NeuroKit, is an optimized reagent kit that enables the mapping of hundreds of genes and cell types via In Situ Sequencing (ISS) in a single tissue section with high throughput and high sensitivity. The company was able to increase the pace of its neurology product development and, at the same time, launched their second product in oncology in 2020.